Finance

Lists
DNPUF:OTCMKTS
Sumitomo Pharma Co Ltd
9,79 US$
0,00%
(0,00) 1D
16 სექ, 15:47:50 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DNPUF...
Mkt. cap
728,16 მლრ.
Avg. vol.
83,00
Volume
0,00
52-wk high
19,20 US$
52-wk low
8,40 US$
Beta
0,38
Shares outstanding
449,20 მლნ.
No. of employees
3 ათ.
Mkt. cap
728,16 მლრ.
Avg. vol.
83,00
Volume
0,00
52-wk high
19,20 US$
52-wk low
8,40 US$
Beta
0,38
Shares outstanding
449,20 მლნ.
No. of employees
3 ათ.
News stories
From web sources and news partners
CNBC
CNBC
·
27 წუთის წინ
How the S&P 500 can be at record highs, while the market remains oversold
MarketForces Africa
MarketForces Africa
·
57 წუთის წინ
XRP Establishes Price Floor Ahead Of Evernorth Nasdaq Listing
MarketBeat
MarketBeat
·
5 წუთის წინ
GDS (NASDAQ:GDS) Stock Jumps 8.2% - Time to Buy?
Bloomberg.com
Bloomberg.com
·
18 საათის წინ
Watch S&P 500 Hits All-Time High on AI Bets as Oil Drops
Profile
Sumitomo Pharma Company Limited is a Japanese multinational pharmaceutical company. The company is focused on oncology, psychiatry, neurology, women's health issues, urological diseases among other areas. Its headquarters are located in Chuo-ku, Osaka. Wikipedia
About Sumitomo Pharma Co Ltd
CEO-
Employees3,12 ათ.
Founded14 მაი. 1897
Headquartersოსაკა, Osaka, იაპონია
SectorPharmaceutical industry
Websitesumitomo-pharma.co.jp
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
119,12 მლრ.
120,62 მლრ.
105,55 მლრ.
129,50 მლრ.
Cost of goods sold
45,59 მლრდ.
55,44 მლრდ.
51,26 მლრდ.
61,41 მლრდ.
Cost of revenue
45,59 მლრდ.
55,44 მლრდ.
51,26 მლრდ.
61,41 მლრდ.
Research and development expenses
9,35 მლრდ.
10,35 მლრდ.
16,12 მლრდ.
11,43 მლრდ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
40,90 მლრდ.
42,94 მლრდ.
43,52 მლრდ.
39,24 მლრდ.
Operating expense
-1,04 მლრდ.
52,19 მლრდ.
110,09 მლრ.
50,33 მლრდ.
Total operating expenses
44,55 მლრდ.
107,63 მლრ.
161,36 მლრ.
111,74 მლრ.
Operating income
74,57 მლრდ.
13,00 მლრდ.
-55,81 მლრდ.
17,75 მლრდ.
Other non operating income
-
-
-1,64 მლრდ.
-
EBT including unusual items
80,87 მლრდ.
8,74 მლრდ.
-1,20 მლრდ.
18,30 მლრდ.
EBT excluding unusual items
80,87 მლრდ.
8,74 მლრდ.
-51,00 მლრდ.
18,30 მლრდ.
Income tax expense
-6,78 მლრდ.
-80,00 მლნ.
-383,00 მლნ.
1,30 მლრდ.
Effective tax rate
-8,39%
-0,92%
32,05%
7,09%
Other operating expenses
-51,30 მლრდ.
-1,10 მლრდ.
50,45 მლრდ.
-337,00 მლნ.
Net income
87,65 მლრდ.
8,82 მლრდ.
-812,00 მლნ.
17,00 მლრდ.
Net profit margin
73,58%
7,31%
-0,77%
13,13%
Earnings per share
-
-
-
-
Interest and investment income
5,11 მლრდ.
258,00 მლნ.
4,64 მლრდ.
2,20 მლრდ.
Interest expense
-
-5,14 მლრდ.
-
-2,09 მლრდ.
Net interest expenses
5,11 მლრდ.
-4,88 მლრდ.
4,64 მლრდ.
107,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
79,85 მლრდ.
18,32 მლრდ.
-52,48 მლრდ.
22,65 მლრდ.
Gain or loss from assets sale
1,96 მლრდ.
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები